Clinical and immunological outcomes of SARS-CoV-2 infection in patients with inborn errors of immunity receiving different brands and doses of COVID-19 vaccines İmmün sistemin doğuştan gelen kusurları olan hastalarda farklı marka ve dozlarda uygulanan SARS-CoV-2 aşısı sonrası SARS-CoV-2 enfeksiyonunun klinik ve immünolojik sonuçları
Tuberkuloz ve Toraks, cilt.71, sa.3, ss.236-249, 2023 (ESCI, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 71 Sayı: 3
- Basım Tarihi: 2023
- Doi Numarası: 10.5578/tt.20239705
- Dergi Adı: Tuberkuloz ve Toraks
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, CAB Abstracts, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.236-249
- Anahtar Kelimeler: Inborn errors of immunity, the Pfizer/BioNTech BNT162b2, Sinovac, SARS-CoV-2, COVID-19 vaccines
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Introduction: Vaccines against severe acute respiratory syndrome-coronavi-rus-2 (SARS-CoV-2) provide successful control of the coronavirus-2019 (COVID-19) pandemic. The safety and immunogenicity studies are encourag-ing in patients with inborn errors of immunity (IEI); however, data about mortality outcomes and severe disease after vaccination still need to be fully addressed. Therefore, we aimed to determine the clinical and immunological outcomes of SARS-CoV-2 infection in patients with IEI who have received vac-cination. Materials and Methods: Eighty-eight patients with a broad range of molecular etiologies were studied; 45 experienced SARS-CoV-2 infection. Infection outcomes were analyzed in terms of genetic etiology, background clinical char-acteristics, and immunization history, including the type and number of doses received and the time elapsed since vaccination. In addition, anti-SARS-CoV-2 antibodies were quantified using electrochemiluminescent immunoassay. Results: Patients were immunized using one of the three regimens: inactivated (Sinovac, Coronavac®), mRNA (BNT162b2, Comirnaty®, Pfizer-Biontech), and a combination. All three regimens induced comparable anti-SARS-CoV-2 IgG levels, with no differences in the adverse events. Among 45 patients with COVID-19, 26 received a full course of vaccination, while 19 were vaccine-naive or received incomplete dosing. No patients died due to COVID-19 infection. The fully immunized group had a lower hospitalization rate (23% vs. 31.5%) and a shorter symptomatic phase than the others. Among the fully vaccinated patients, serum IgM and E levels were significantly lower in hospitalized patients than non-hospitalized patients. Conclusion: COVID-19 vaccines were well-tolerated by the IEI patients, and a full course of immunization was associated with lower hospitalization rates and a shorter duration of COVID-19 symptoms.